Background colour

PREVIEW

Video

AssetID: 54044105

Headline: NHS Rejects Alzheimer's Drug Lecanemab Over Cost Concerns Despite Approval Elsewhere

Caption: The NHS in England will not offer the first drug to slow early-stage Alzheimer's, Lecanemab, due to concerns that the benefits do not justify its high costs, according to NICE (National Institute for Health and Care Excellence), BBC News reports. Lecanemab, approved by the UK's MHRA, is available privately but not on the NHS; the drug slows cognitive decline by about 25% over 18 months

Keywords: NHS,Rejects,Alzheimer,Drug,Lecanemab,Over,Cost,Concerns,Despite,Approval,Elsewhere,Japan,UK,National Institute for Health and Care Excellence,NICE,England,Hospitals,Patients,Restrictions,Brain,Protein,Risks,Benefits,China,US,PET Brain Scans,Lumbar Punctures

PersonInImage: